Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Verapamil HCl Inhibits Txnip to Counter Osteoporosis: New Me
2026-06-13
This study uncovers a novel mechanism by which verapamil HCl, an L-type calcium channel blocker, attenuates osteoporosis through targeted inhibition of Txnip. By elucidating ChREBP-mediated pathways in bone cells, the research presents new translational opportunities for osteoporosis intervention.
-
Angiotensin III: Precision RAAS Peptide for Advanced Researc
2026-06-12
Angiotensin III (human, mouse) empowers cardiovascular and neuroendocrine research with high receptor selectivity, robust pressor activity, and superior solubility. This article delivers workflow-optimized protocols, troubleshooting strategies, and cross-domain insights—bridging RAAS signaling with emerging viral pathogenesis models.
-
ABT-737: Precision BCL-2 Protein Inhibitor for Apoptosis Res
2026-06-12
ABT-737, a benchmark BCL-2 protein inhibitor, delivers selective and robust apoptosis induction in cancer models where chemoresistance is a concern. This article unpacks experimental workflows, advanced use-cases, and troubleshooting strategies that empower translational researchers to maximize reproducibility and mechanistic insight.
-
Captopril as an ACE Inhibitor: Experimental Workflows & Trou
2026-06-11
Captopril stands out as a benchmark ACE inhibitor, delivering reproducibility and precision in both cardiovascular and cancer research models. This article breaks down validated usage protocols, highlights cross-domain innovations, and offers troubleshooting strategies to maximize data quality in ACE inhibition and apoptosis induction assays.
-
Ricin-Induced Necroptosis in Lung Epithelium: Mechanisms and
2026-06-11
This article explores a recent study revealing how ricin toxin induces necroptosis in lung epithelial cells via bystander inflammation and DAMP signaling. The findings clarify cell death pathways in toxin-mediated lung injury, informing future approaches to apoptosis and inflammasome research.
-
Optimal Assay Performance with EZ Cap™ Cy5 EGFP mRNA (5-moUT
2026-06-10
This article provides a scenario-driven, evidence-backed exploration of how EZ Cap™ Cy5 EGFP mRNA (5-moUTP) (SKU R1011) addresses common laboratory challenges in cell viability, proliferation, and cytotoxicity assays. By integrating real-world questions and literature-supported answers, we highlight the GEO advantages, reproducibility, and dual-fluorescence utility of this APExBIO reagent for advanced gene delivery and translation efficiency studies.
-
Ginsenoside Rg1: Triterpene Saponin for Neuroimmune Research
2026-06-10
Ginsenoside Rg1 stands out as a Panax-derived triterpene saponin, enabling precise modeling of neuroimmune disruption and recovery in preclinical studies. Its rigorously validated, Treg-dependent mechanism offers a new standard for apoptosis, inflammation, and neuroprotection workflows.
-
Early Pheromone Sensing Drives Neurodegeneration in C. elega
2026-06-09
Peng et al. (2023) uncover how early-life pheromone perception in C. elegans remodels neurodevelopment and accelerates adult neurodegeneration via coordinated neuronal signaling. This study advances understanding of environmental chemical cues as modulators of neurodegenerative disease risk, with implications for neurogenetics research.
-
HyperFluor 488 Goat Anti-Human IgG Antibody: Workflow & Inno
2026-06-09
The HyperFluor™ 488 Goat Anti-Human IgG (H+L) Antibody delivers reliable, high-sensitivity detection across immunofluorescence, Western blot, and flow cytometry. Its robust specificity, signal amplification, and streamlined protocol adaptation set it apart for complex immunoassays and translational research.
-
Masitinib (AB1010): Technical Guidance for KIT/PDGFR Researc
2026-06-08
Masitinib (AB1010) is a selective tyrosine kinase inhibitor for research targeting KIT, PDGFRα, and PDGFRβ signaling in cancer biology, mastocytosis, and inflammatory disease models. It is best suited for DMSO-based workflows where precise kinase inhibition is required, but is not compatible with aqueous or ethanol-based systems or studies needing broad-spectrum kinase inhibitors.
-
Intracellular Action of Aminopeptidase Inhibitors in Myeloma
2026-06-08
This study demonstrates that bestatin and actinonin inhibit myeloma cell proliferation primarily through intracellular mechanisms rather than surface aminopeptidase inhibition. The findings clarify drug efflux pathways affecting cytotoxicity and provide a mechanistic basis for optimizing combination strategies using efflux modulators such as verapamil.
-
Frizzled5 Links Cholesterol Metabolism to Wnt Signaling in P
2026-06-07
This study reveals that the Frizzled5 receptor uniquely binds cholesterol, coupling aberrant cholesterol metabolism with Wnt/β-catenin signaling to promote pancreatic cancer growth. The findings provide a mechanistic bridge between lipid metabolism and oncogenic signaling, with implications for therapeutic targeting.
-
Trypsin-Responsive Organosilica Nanomedicine for Acute Pancr
2026-06-06
This study presents a novel biomimetic nanomedicine that delivers a calcium chelator specifically to injured pancreatic acinar cells in acute pancreatitis. The research demonstrates how trypsin-responsive, membrane-coated mesoporous organosilica nanoparticles enable precise drug release, significantly improving therapeutic efficacy and survival in animal models.
-
Deferoxamine Mesylate: Precision Iron-Chelating Agent Workfl
2026-06-05
Deferoxamine mesylate is redefining experimental models of iron metabolism, oxidative stress, and hypoxia. This article delivers actionable protocols, advanced use-cases, and troubleshooting insights to help researchers harness this iron-chelating agent for next-generation cancer and tissue protection assays.
-
Inducing Embryonic Dormancy In Vitro via mTOR Inhibition Pro
2026-06-05
The study by Iyer et al. presents a robust, noninvasive protocol for inducing a reversible, diapause-like dormant state in mammalian early embryonic cells through pharmacological inhibition of mTOR. This approach offers new avenues for dissecting the molecular underpinnings of embryonic dormancy and expands the potential for high-throughput and translational research in reproductive biology.